Press Releases

Date Title and Summary Additional Formats
Toggle Summary New Study Further Demonstrates In Vitro Activity of SCYNEXIS' Lead Anti-Infective Candidate, SCY-078, Against Drug-Resistant Candida Fungal Strains
Supports SCY-078's Activity Against Emerging Echinocandin-Resistant Candida Species
View HTML
Toggle Summary SCYNEXIS, Inc. to Participate in the 2017 BIO International Convention
JERSEY CITY, N.J., June 13, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced that Marco Taglietti, M.D., President and Chief Executive Officer,
View HTML
Toggle Summary Eight Presentations at ASM Microbe 2017 Further Highlight the Strong Antifungal Effect and Promising Safety Profile of Lead Anti-Infective Candidate SCY-078
Potent and broad activity of SCY-078 shown against more than 300 clinical Candida isolates    Multiple studies confirm high compatibility of SCY-078 with other antifungals and favorable safety profile   JERSEY CITY, N.J., June 05, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc.
View HTML
Toggle Summary Eight SCY-078 Data Presentations at ASM Microbe 2017 Confirm Potential of SCYNEXIS' Lead Agent to Combat Serious and Life-threatening Fungal Infections
JERSEY CITY, N.J., May 24, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced eight poster presentations at ASM Microbe 2017 , June 1 through 5 in
View HTML
Toggle Summary Potent in vitro Activity of SCYNEXIS' SCY-078 Against Multidrug-Resistant Fungal Pathogen Candida auris Further Confirmed in an in vitro Study Conducted by the Centers for Disease Control and Prevention (CDC)
SCY-078 may provide a therapeutic option for this emerging pathogen classified as a serious global health threat by the CDC Multiple studies confirm SCY-078's broad spectrum of activity against Candida species, including resistant strains JERSEY CITY, N.J., May 11, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS
View HTML
Toggle Summary SCYNEXIS Reports First Quarter 2017 Financial Results and Provides Update on IV Formulation Development Status
JERSEY CITY, N.J., May 08, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today reported financial results for the quarter ended March 31, 2017, and provided
View HTML
Toggle Summary Eight Data Presentations at ECCMID Showcase the Broad Applicability of SCYNEXIS' Lead Anti-infective Candidate SCY-078
Presentations support SCY-078's potential as a novel treatment for  Candida infections including multidrug-resistant strains Favorable safety profile of SCY-078 supported by clinical studies presented Conference call to review ECCMID SCY-078 data to be held April 25 at 4:05 p.m.
View HTML
Toggle Summary SCYNEXIS to Host a Conference Call to Discuss Lead Anti-Infective Candidate SCY-078 Data Presented at 27th ECCMID
JERSEY CITY, N.J., April 21, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced that it will hold a conference call at 4:05 p.m.
View HTML
Toggle Summary SCYNEXIS to Present SCY-078 Data on Novel Lead Anti-infective Candidate at 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Oral presentation of Phase 2 study discusses oral SCY-078 in patients with invasive candidiasis Potent in vitro activity of SCY-078 against multidrug-resistant fungal pathogen Candida auris In vitro synergy of SCY-078 in combination with other antifungals against Aspergillus Additional posters
View HTML
Toggle Summary SCYNEXIS, Inc. to Present at the 16th Annual Needham Healthcare Conference
JERSEY CITY, N.J., March 29, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a drug development company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs, today announced that the Company will present at the 16 th
View HTML